About ct p
HER2-targeted monoclonal antibody
Used for
- HER2-positive breast cancer
- HER2-positive metastatic gastric or gastroesophageal junction cancer
Usual adult dose
Breast cancer: 8 mg/kg IV loading dose, then 6 mg/kg every 3 weeks; other regimens vary. Gastric cancer: 8 mg/kg loading, then 6 mg/kg every 3 weeks.
Common side effects
- Infusion reactions, fever, chills
- Diarrhea, nausea, headache
- Heart muscle weakness or heart failure
- Infections and low blood counts
Important warnings
- Heart function should be assessed before and during treatment.
- Severe infusion reactions can occur, especially with early doses.
- May harm an unborn baby; pregnancy testing and effective contraception are recommended.
- Use in HER2-positive disease only; confirm tumour status before treatment.
Pregnancy
Can cause fetal harm, including low amniotic fluid. Avoid during pregnancy unless essential; effective contraception during treatment and for 7 months afterward.
Breastfeeding
Breastfeeding is generally not recommended during treatment and for 7 months after the final dose.
Interactions
- Anthracycline chemotherapy may increase heart damage, including after trastuzumab ends.
- Other chemotherapy can increase toxicity; treatment schedules require specialist oversight.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.